Drug Profile
Research programme: Helicobacter pylori vaccine - MIVAC Development
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Sahlgrenska Academy
- Developer MIVAC Development
- Class Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Helicobacter infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Helicobacter-infections in Sweden
- 21 Jul 2011 Preclinical trials in Helicobacter infections in Sweden (unspecified route)